Omnicell, Inc. (OMCL)
| Market Cap | 1.99B +35.7% |
| Revenue (ttm) | 1.23B +7.9% |
| Net Income | 20.43M -3.5% |
| EPS | 0.44 -2.8% |
| Shares Out | 45.48M |
| PE Ratio | 99.53 |
| Forward PE | 23.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 456,237 |
| Open | 43.62 |
| Previous Close | 43.17 |
| Day's Range | 42.54 - 43.85 |
| 52-Week Range | 26.85 - 55.00 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 55.83 (+27.47%) |
| Earnings Date | Apr 28, 2026 |
About OMCL
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-hous... [Read more]
Financial Performance
In 2025, Omnicell's revenue was $1.18 billion, an increase of 6.53% compared to the previous year's $1.11 billion. Earnings were $2.05 million, a decrease of -83.62%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for OMCL stock is "Buy." The 12-month stock price target is $55.83, which is an increase of 27.47% from the latest price.
News
Omnicell Transcript: Bank of America Global Healthcare Conference 2026
The conference highlighted a strategic focus on launching Titan XT and OmniSphere, driving a major product transition and targeting margin expansion through disciplined execution and investment. Management expects a multi-year capital cycle, stable hospital CapEx, and renewed optimism in retail pharmacy.
Omnicell to Present at the BofA Securities 2026 Healthcare Conference
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the BofA Securities 2026 Healthcare Conference.
Omnicell price target raised to $55 from $53 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Omnicell (OMCL) to $55 from $53 and keeps a Buy rating on the shares. Following the company’s beat and raise quarter, the firm…
Omnicell appoints Rick Couldry as SVP, chief pharmacy and clinical officer
Omnicell (OMCL) announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. In this newly created position, Couldry will serve as Omnicell’s senio...
Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer.
Omnicell price target raised to $70 from $60 at KeyBanc
KeyBanc raised the firm’s price target on Omnicell (OMCL) to $70 from $60 and keeps an Overweight rating on the shares. After a solid Q1, the firm continues to recommend…
Omnicell price target raised to $70 from $60 at KeyBanc
KeyBanc raised the firm’s price target on Omnicell (OMCL) to $70 from $60 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1…
Omnicell Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded guidance with 15% revenue growth, improved margins, and strong recurring revenue momentum. Full-year guidance was raised for EBITDA and EPS, supported by robust demand for new platforms and disciplined cost management.
Omnicell reports Q1 adjusted EPS 55c, consensus 33c
Reports Q1 revenue $310M, consensus $304.06M. “We delivered a strong start to 2026, driven by solid execution and sustained demand for our points of care solutions,” said Randall Lipps, chairman,…
Omnicell sees Q2 adjusted EPS 40c-48c, consensus 42c
Sees Q2 revenue $307M-$313M, consensus $304.83M.
Omnicell raises FY26 adjusted EPS view to $1.80-$2.00 from $1.65-$1.85
FY26 consensus $1.77. Backs FY26 revenue view $1.215B-$1.255B, consensus $1.24B.
Omnicell Announces First Quarter 2026 Financial Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces First Quarter 2026 Financial Results.
Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026.
Omnicell management to meet with Piper Sandler
Meeting to be held on March 12 hosted by Piper Sandler.
Omnicell management to meet virtually with Benchmark
Virtual Meeting to be held on March 11 hosted by Benchmark.
Omnicell price target lowered to $49 from $63 at Piper Sandler
Piper Sandler lowered the firm’s price target on Omnicell (OMCL) to $49 from $63 and keeps an Overweight rating on the shares. The firm notes the company reported mixed Q4…
Omnicell Earnings Call Transcript: Q4 2025
Delivered strong Q4 and FY 2025 results, exceeding guidance for revenue, bookings, and ARR. Launched Titan XT and expanded OmniSphere, driving robust demand and competitive wins. FY 2026 guidance anticipates continued growth, with investments in innovation, cloud, and sales force.
Omnicell reports Q4 adjusted EPS 40c, consensus 50c
Reports Q4 revenue $314M, consensus $313.36M. “We finished 2025 with solid fourth quarter financial results, delivering full year 2025 total revenues, product bookings and annual recurring revenues al...
Omnicell sees Q1 adjusted EPS 26c-36c, consensus 27c
Sees Q1 revenue $300M-$310M, consensus $280.84M.
Omnicell sees FY26 adjusted EPS $1.65-$1.85, consensus $1.88
Sees FY26 revenue $1.215B-$1.255B, consensus $1.24B.
Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results.
Omnicell management to meet with Piper Sandler
Meeting to be held in Boston on February 11 and in New York on February 12 hosted by Piper Sandler.
Omnicell upgraded to Buy at BofA on new product cycle
As previously reported, BofA analyst Allen Lutz upgraded Omnicell (OMCL) to Buy from Neutral with a price target of $70, up from $53, as the firm sees a significant upside…
Omnicell upgraded to Buy from Neutral at BofA
BofA upgraded Omnicell (OMCL) to Buy from Neutral with a price target of $70, up from $53.
Omnicell price target raised to $60 from $50 at Benchmark
Benchmark raised the firm’s price target on Omnicell (OMCL) to $60 from $50 and keeps a Buy rating on the shares ahead of the company reporting its 2026 results on…